Sanjiv S. Agarwala, MD
Professor, Temple University School of Medicine
Sanjiv S. Agarwala, MD is Professor of Medicine at Temple University School of Medicine in Philadelphia. Dr. Agarwala is nationally and internationally recognized as an expert in melanoma research and treatment and cancer immunotherapy, and he has presented and led numerous conferences and meetings across the globe.
Dr. Agarwala completed his medical training through residencies and fellowships at the University of Bombay in India, the University of Otago in New Zealand, and the University of Pittsburgh in Pennsylvania.
Dr. Agarwala has written and contributed to over 200 publications and book chapters on melanoma, immuno-oncology, and other research areas. He is board certified in oncology and hematology and is an active member of several professional and scientific societies, such as the American Association for Cancer Research, the American Society of Clinical Oncology, the European Society of Medical Oncology, and the Society for Melanoma Research.
Paul A. Bunn, Jr., MD
Division of Medical Oncology
James Dudley Chair of Lung Cancer Research
University of Colorado Cancer Center
Dr. Paul A. Bunn, Jr. is a Distinguished Professor and the James Dudley Chair of Lung Cancer Research in the Division of Medical Oncology at the University of Colorado Cancer Center of the University of Colorado School of Medicine, where he has practiced and taught since 1984.
Dr. Bunn received his BA from Amherst College in Amherst, MA, and received his MD from Weill Cornell Medical College in New York City. He completed an internship and residency at the University of California San Francisco and a fellowship in medical oncology at the National Cancer Institute (Bethesda) Program. He is board certified in internal medicine and medical oncology. Dr. Bunn served as the Head of the Division of Medical Oncology from 1984-1992 and as the Director of the University of Colorado Cancer Center from 1986-2009. In the IASLC, Dr. Bunn served on the board of directors from 1988 to 1994, as president from 1997-2000, and as CEO from 2004-2014. Dr. Bunn also served as president of ASCO from 2002-2003.
The author of hundreds of articles, reviews, and book chapters, Dr. Bunn’s research is well known in the cancer world. He focuses primarily on novel therapies for lung cancer. Dr. Bunn has led numerous national and local trials regarding the treatment of lung cancer, and his findings are credited with setting standards in the treatment of the disease.
Dr. Bunn has researched new personalized therapies for lung cancer that cause fewer side effects than traditional, intravenous chemotherapy. He has also studied the genetics of the disease, seeking to learn how gene therapy could be used to combat it. He was the Principal Investigator on the Specialized Program in Research Excellence in Lung Cancer (SPORE) grant funded by the National Institutes of Health and the National Cancer Institute from 1992-2019.
Jorge J. García, PharmD, MS, MHA, MBA, FACHE
Assistant Vice President
System Oncology Pharmacy Services
Non-Oncology Infusion Center Pharmacy Services
Corporate Pharmacy Clinical Enterprise
Miami Cancer Institute
Baptist Health South Florida
Member, Memorial Sloan Kettering Cancer Alliance
Jorge J. García obtained his Doctor of Pharmacy (PharmD) and Master of Business Administration (MBA) from Nova Southeastern University in 2010. He then transitioned to the University of Pittsburgh Medical Center to pursue an American Society of Health-System Pharmacy (ASHP)-accredited PGY-1 & PGY-2 Health-System Pharmacy Administration Residency and a Master of Science (MS) in Pharmacy Administration. He also obtained a Master of Healthcare Administration (MHA) from Florida Atlantic University. Dr. García has previously served in the roles of inpatient pharmacy operations coordinator as well as director of pharmacy for system-wide oncology pharmacy services.
Dr. García currently serves as Assistant Vice President at Baptist Health South Florida with responsibility for system-wide acute and ambulatory oncology pharmacy services as well as non-oncology infusion pharmacy services. Dr. García has pioneered pharmacy charge integrity and revenue management in the health-system setting and is a thought leader and national speaker in this area, as well as in the areas of alternative payment models, biosimilars, and value-based oncology care. Dr. García leads advocacy efforts at the national level to promote evaluation of safe and effective use of biosimilars, along with stakeholders’ engagement to support a more sustainable biosimilar pharmacoeconomic model. Dr. García has served as a board member at Florida Society of Clinical Oncology (FLASCO) since 2015 and is also a previous recipient of the FLASCO Above and Beyond Award, which honored his exceptional dedication and innovative contributions to the society. Dr. García also currently holds multiple committee appointments at the Association of Community Cancer Centers (ACCC), including the Oncology Pharmacy Education Network and the National Biosimilar Taskforce. In 2020, Dr. García was also appointed to the Board of Trustees at ACCC. In addition, Dr. García currently serves as faculty for the ASHP Foundation Pharmacy Leadership Academy. Dr. García is a fellow of the American College of Healthcare Executives.
William J. Gradishar, MD, FACP
Chief of Hematology and Oncology
Department of Medicine
Betsy Bramsen Professorship of Breast Oncology
Professor of Medicine
Northwestern Medicine Feinberg School of Medicine
William J. Gradishar, MD, FACP, is a Betsy Bramsen Professor of Breast Oncology and Professor of Medicine and Deputy Chief in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. He is also Director of the Lurie Cancer Center’s Maggie Daley Center for Women’s Cancer Care, where he develops and implements clinical trials. He completed his residency at the University of Illinois College of Medicine in Chicago.
Dr. Gradishar is a fellow of both the American Society of Clinical Oncology (ASCO) and the American College of Physicians, as well as a member of the American Association for Cancer Research and the American Federation for Medical Research. He has held numerous leadership positions at ASCO and has been a member of numerous study sections for funding agencies, including the Department of Defense, the National Institutes of Health, the Susan G. Komen Foundation, and the American Cancer Society. He has served as a consultant to the US Food and Drug Administration’s Oncology Drug Advisory Committee, and he is a member of the Breast Cancer Core Committee of the Eastern Cooperative Oncology Group.
Dr. Gradishar is a member of the editorial boards of the Journal of Clinical Oncology, Clinical Breast Cancer, Current Treatment Options in Oncology, and Oncology. He is the currently the editor-in-chief of NEJM Journal Watch: Oncology and Hematology.
Thomas J. Herzog, MD
Deputy Director, University of Cincinnati Cancer Center
Paul & Carolyn Flory Endowed Professor
Obstetrics and Gynecology
University of Cincinnati College of Medicine
Dr. Thomas Herzog is the Deputy Director of the University of Cincinnati Cancer Center. He is also Vice-Chair of Quality and Safety for Obstetrics and Gynecology, University of Cincinnati College of Medicine. From 2004 to 2014 he was the Director of Gynecologic Oncology and the Physicians & Surgeons Endowed Professor of Clinical Gynecology and Obstetrics at Columbia University. He also was the Fellowship Director in Gynecologic Oncology for Columbia & Cornell Universities and New York Presbyterian Hospitals. Prior to 2004, he was an Associate Professor and the Director of the Fellowship Training Program at Washington University in St. Louis. He is Secretary Treasurer of the GOG-Foundation and is Associate Director of GOG Partners.
Dr. Herzog has authored/co-authored over 300 peer-reviewed articles and lectures extensively, both nationally and internationally. He serves or has served on the editorial boards of Gynecologic Oncology, Obstetrics and Gynecology International, Hematology Oncology Times, and others. He served as Editor-in-Chief of both Women’s Oncology Review and Gynecologic Oncology Research to Practice.
Dr. Herzog has served on the board of directors or leadership council of the Society of Gynecologic Oncology, the Foundation for Women’s Cancer, Board of Governors for the American College of Surgeons, American Board of Obstetrics and Gynecology, and the International Gynecologic Cancer Society.
Sara A. Hurvitz, MD
Professor of Medicine at the University of California Los Angeles (UCLA)
Co-Director of the Santa Monica-UCLA Outpatient Oncology Practice
Medical Director of the Clinical Research Unit of the Jonsson Comprehensive Cancer Center of UCLA, and Director of the Breast Oncology Program, Division of Hematology-Oncology at UCLA
Sara A. Hurvitz, MD is Professor of Medicine, Co-Director of the Santa Monica-UCLA Outpatient Practice, Medical Director of the Clinical Research Unit of the Jonsson Comprehensive Cancer Center, and Director of Breast Oncology at UCLA. Dr. Hurvitz earned her MD from the University of Southern California. She completed her internship/residency, served as Chief Resident of internal medicine, and completed a hematology-oncology fellowship at UCLA in 2006. Dr. Hurvitz received board certification in internal medicine, hematology, and medical oncology.
Dr. Hurvitz has won numerous awards over the past few years, such as the Marni Levine Memorial Breast Cancer Research Award from 2008 through 2015. She has an active clinical practice specializing in the treatment of women with breast cancer. She is involved in designing, implementing, and leading multiple national and international clinical trials testing new targeted therapies and also leads the preclinical evaluation of novel breast cancer targets in the Translation Oncology Research Laboratory at UCLA.
Brian A. Jonas, MD, PhD, FACP
Associate Professor of Medicine
Chair, Hematologic Malignancies Disease Team Committee
Division of Hematology and Oncology
University of California Davis School of Medicine
Brian A. Jonas, MD, PhD, FACP has clinical and research interests in acute myeloid leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, and other myeloid malignancies. He leads the acute Leukemia and MDS Research Program and is chair of the Hematologic Malignancies Disease Team at the UC Davis Comprehensive Cancer Center. His research focuses on developmental therapeutics and biomarker development, with an emphasis on early drug development and leukemia stem cells.
Sagar Lonial MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Sagar Lonial, MD, FACP is internationally recognized as a leading authority in multiple myeloma treatment and research. As a medical oncologist at the Winship Cancer Institute, Dr. Lonial treats patients with multiple myeloma and is a lead member of the bone marrow transplantation team and clinical trials team. He is board certified in hematology and medical oncology.
Dr. Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology and oncology at Emory University School of Medicine in Atlanta, Georgia.
Dr. Lonial has worked in the field of immunotherapy and cancer since his arrival at Emory, and in the previous 3 years has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. His previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen, and he has completed several trials evaluating the impact of cytokines on dendritic cell content and post-transplant immune recovery.
Most recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma, particularly evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway. His lab has recently received funding from the MMRF, the Lymphoma Research Foundation, and the Leukemia & Lymphoma Society.
Dr. Lonial has authored or co-authored over 200 peer-reviewed publications. He serves on the editorial board of the Journal of Clinical Oncology and Leukemia; is the myeloma editor for Clinical Lymphoma, Myeloma and Leukemia; and is the hematologic malignancies section editor for the journal Cancer. In addition, he is an invited or ad hoc reviewer for several publications, including Blood, Haematologica, Clinical Cancer Research, The New England Journal of Medicine, and others.
Jessica MacIntyre, MSN, APRN, NP-C, AOCNP
Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine
Jessica MacIntyre, MSN, APRN, NP-C, AOCNP entered the field of oncology in 2000 after graduating with her BSN from the University of Miami. She has been practicing at Sylvester for over 16 years in various roles. Of note, she was the first nurse navigator for the Pancreatic, Liver, and Related Cancers Site Disease Group at Sylvester. She later pursued her Master’s degree at Florida International University and now practices as an Advanced Practice Registered Nurse (APRN). She also functions as the Executive Director of Clinical Operations for Sylvester Comprehensive Cancer Center. She is currently pursuing a dual degree (MBA/DNP) at Johns Hopkins University.
In her current role, she oversees various programs including oncology social work, cancer support services, nurse navigation, cancer survivorship, and phase 1 clinical research operations. She developed the first Patient and Family Advisory Council for Sylvester and is also the current chair of this group. Jessica was past president of the Miami-Dade Chapter of the Oncology Nursing Society as well as the past president of the Nurse Practitioner Council of Miami-Dade, Inc. Additionally, she has publications in the area of gastrointestinal malignancies and is an avid speaker on topics concerning supportive care for the oncology patient. Most recently she co-developed the first Oncology Nurse Practitioner Fellowship Program at University of Miami (the first in Florida).
Ravi A. Madan, MD
Genitourinary Malignancies Branch Center for Cancer Research
National Cancer Institute
Ravi A. Madan, MD, is Senior Clinician and the Clinical Director of the Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland. His clinical research is focused on immune-stimulating therapies and prostate cancer. Specifically, Dr. Madan’s clinical trials are designed to develop a better understanding of how immune-stimulating therapies can improve clinical outcomes and be combined with other therapies.
Dr. Madan has vast expertise in cancer, including immunotherapy, prostate cancer, therapeutic cancer vaccines, immune checkpoint inhibitors, metastatic prostate cancer, and medullary thyroid cancer. He also is looking at ways to improve current therapies for prostate cancer and develop new therapies to treat advanced prostate cancer.
Ursula A. Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Ursula A. Matulonis, MD, is Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She is the first recipient of the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute. She co-leads the Gynecologic Cancer Program within the Dana-Farber/Harvard Cancer Center and the Ovarian Cancer Specialized Program in Research Excellence (SPORE) grant from the NCI. Her research focuses on developing new targeted therapies for gynecologic malignancies, with a specific interest in ovarian cancer and endometrial cancer.
Dr. Matulonis has led several PARP inhibitor, anti-angiogenic agent, immunotherapy, and combination trials for ovarian cancer in the United States and internationally. Dr. Matulonis serves on the Massachusetts Ovarian Cancer Task Force, the NRG ovarian committee, the Scientific Advisory Board for the Ovarian Cancer Research Alliance, the Clearity Foundation, and Overcome. She has received the Dana-Farber Dennis Thompson Compassionate Care Scholar Award, the Lee M. Nadler “Extra Mile” Award, the Clearity Foundation Award, the Zakim Award at Dana-Farber for patient advocacy, and recently in 2020, the Albany Medical College Alumni Association Distinguished Alumna Award.
After receiving her MD from Albany Medical College, she completed an internship and residency at the University of Pittsburgh, followed by a medical oncology fellowship at the Dana-Farber Cancer Institute in Boston, MA.
Michelle Melisko, MD
Clinical Professor of Medicine
University of California San Francisco (UCSF)
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Dr. Melisko is a Clinical Professor of Medicine at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. She is interested in testing novel chemotherapy combinations, biological therapies, and immunotherapies for breast cancer, with an emphasis on therapies to treat central nervous system metastases. Dr. Melisko has conducted studies evaluating clinical and molecular markers that predict the development of and prognosis after diagnosis of brain metastases, has investigated assays to diagnose and assess response to leptomeningeal carcinomatosis, and reported on molecular signatures of tumor cells in the cerebrospinal fluid. She has been a principal investigator for multiple investigator initiated and industry sponsored clinical trials in metastatic breast cancer and CNS disease.
Dr. Melisko is co leader of the Patient Reported Outcomes working group in the Translational Breast Cancer Research Consortium and helped develop and lead the Quality of Life/Patient Reported Outcomes within the ISPY neoadjuvant clinical trial. She is the medical director of the UCSF Breast Cancer Survivorship Program and has led trials on quality of life and lifestyle change in breast cancer patients. She is an active member of the NCCN Survivorship Guideline Committee.
Dr. Melisko graduated from Duke University, received her MD from the Wake Forest University School of Medicine, completed residency in internal medicine at Stanford University Hospital and fellowship in hematology and oncology at UCSF.
Shane Y. Morita, MD, MS, PhD, FACS
Medical Director of Surgical Oncology
The Queen's Medical Center
Shane Y. Morita, MD, MS, PhD, FACS, was born and raised in Hilo, Hawaii. He received his medical degree from the University of Hawaii/John A. Burns School of Medicine (JABSOM). Also at JABSOM, Dr. Morita obtained his MS analyzing thyroid cancer in the Filipino population and his PhD investigating cutaneous melanoma in the Native Hawaiian/Pacific Islander population.
Dr. Morita completed his internship and residency at Harbor-UCLA Medical Center/David Geffen School of Medicine at the University of California Los Angeles. He then returned home to be with his father who was diagnosed with terminal cancer in 2004, and worked at North Hawaii Community Hospital until his passing. He personally witnessed the bravery that his father exhibited in fighting his illness and the dedication that his mother exhibited during this trying time. Dr. Morita subsequently performed fellowships at the National Cancer Institute/National Institutes of Health and at The Johns Hopkins Hospital/The Johns Hopkins University School of Medicine.
Dr. Morita is the medical director of surgical oncology and vice chief-elect for the Queen’s Medical Center, certified member in surgical oncology of the MD Anderson Physicians Network, associate professor of surgery for the John A. Burns School of Medicine, and head of surgical oncology for the University of Hawaii Cancer Center. He is the past chair for the Hawaii Comprehensive Cancer Coalition and serves on the board of directors as treasurer for the Hawaii Society of Clinical Oncology. Dr. Morita is a fellow of the American College of Surgeons and a member of the Society of Surgical Oncology and the American Society of Clinical Oncology. He is the chair-elect and chief medical officer of the American Cancer Society Hawaii affiliate. He is principal editor for the Textbook of Complex General Surgical Oncology that is globally distributed by McGraw-Hill Medical. He was selected by Honolulu magazine as the inaugural recipient for the Community Healthcare Leadership Award. He is currently listed as a Top Doctor and Best Doctor in Hawaii.
Susan O’Brien, MD
Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center
Medical Director, Sue and Ralph Stern Center for the Cancer Clinical Trials and Research
Chao Family Endowed Chair for Cancer Clinical Science
Professor of Medicine, Division of Hematology Oncology
University of California Irvine
Susan O’Brien, MD is Associate Director for Clinical Science for the Chao Family Comprehensive Cancer Center, Medical Director of the Sue and Ralph Stern Center for the Cancer Clinical Trials and Research, and the Chao Family Endowed Chair for Cancer Clinical Science at the University of California Irvine. She earned her medical degree and completed her residency in internal medicine at the University of Medicine and Dentistry of New Jersey (UMDNJ) Medical School. Dr. O’Brien completed her fellowship and spent many years at MD Anderson Cancer Center, Houston, TX.
Dr. O’Brien has been principal investigator for more than 100 funded clinical research protocols and has authored more than 800 articles in peer-reviewed journals, 30 invited articles, and numerous book chapters and abstracts. She is the hematology representative to the Southwest Oncology Group Executive Committee, and the hematology editor for the journal Cancer. She serves on the Medical Scientific Advisory Board for the Leukemia and Lymphoma Society. Year after year, she has been repeatedly ranked nationally as top in her field by America’s Top Doctors, Super Docs, and America’s Top Doctors for Cancer.
Luis E. Raez, MD, FACP, FCCP
President, Florida Society of Clinical Oncology (FLASCO)
Chief Scientific Officer & Medical Director
Memorial Cancer Institute/Memorial Health Care System
Clinical Professor of Medicine
Herbert Wertheim College of Medicine
Florida International University
Luis E. Raez, MD, FACP, FCCP is the Medical Director of Memorial Cancer Institute, the Oncology Research Director of Memorial Health Care System, Director of the Thoracic Oncology Program, the Clinical Associate Professor of Medicine at Florida International University, and Visiting Professor of Medicine at Cayetano Heredia University in Peru. Currently Dr. Raez designs phase 1-3 clinical trials with new chemotherapeutic agents and combinations. Dr. Raez does translational research in the areas of cancer vaccines and has been funded by NCI and the pharma industry. Dr. Raez has given oral presentations and lectures in national and international meetings in the US, Europe, Latin America and Asia. He is American Board Certified in internal medicine, medical oncology, and geriatric medicine. He is board elegible in hematology. Dr. Raez is a member of AACR, ESMO, ASCO, IASLC, ALLIANCE, NCCTG, ACCP, ACP, ACSG, and FLASCO, among other institutions.
Kanwal Raghav, MD
Department of GI Medical Oncology
MD Anderson Cancer Center
Dr. Kanwal Raghav is an Associate Professor in the Department of Gastrointestinal Medical Oncology (GIMO) at MD Anderson Cancer Center, Houston, TX. His clinical and research efforts center on patients with colorectal cancer (CRC) and rare GI malignancies (peritoneal mesothelioma, cholangiocarcinoma, appendix and small bowel adenocarcinomas, cancer of unknown primary) with emphasis on cancer genomics and developmental therapeutics. He joined GIMO after completing his residency and fellowship in hematology/oncology in 2013 and since has led many clinical trials (targeted therapy and combined targeted and immune therapy) as principal investigator and authored multiple publications on tumor biology, therapeutic resistance, and cancer biomarkers. His research focuses on biomarker-based cancer therapy and genomically-driven clinical trials. Specifically, he and his team have been working on identifying putative predictive biomarkers for EGFR antibody resistance in CRC (such as HER2 amplification) using next-generation sequencing and ctDNA assays and have validated HER2 amplification as a predictive biomarker in mCRC. He has been involved in multiple clinical trials for this subset of CRC. He is a co-investigator on MyPathway HER2 targeting (trastuzumab + pertuzumab) study in mCRC, the National Principal Investigator of S1613 (NCI-NCTN study) “A randomized trial of cetuximab plus irinotecan (CETIRI) vs. trastuzumab plus pertuzumab (TP) in patients with refractory HER2 amplified metastatic colorectal cancer” and principal investigator for DS8201-A-J203 study “A phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancer”.
Hope S. Rugo, MD, FASCO
Professor of Medicine
Director of Breast Oncology and Clinical Trials Education
University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Hope S. Rugo, MD, FASCO is a medical oncologist specializing in breast cancer research and treatment. Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at University of California San Francisco (UCSF) in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer. She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer.
Dr. Rugo is the Director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center. She is a principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late-stage breast cancer, and has published widely in this area. Her current research interests include immunotherapy and combinations of targeted agents in the treatment of breast cancer to overcome resistance. In addition, Dr. Rugo has conducted a number of studies focusing on reducing toxicity from therapy, resulting in approval of scalp cooling to reduce chemotherapy induced hair loss, and a steroid mouthwash to reduce targeted agent stomatitis. She is an investigator and the chair of the safety committee for the multicenter adaptively randomized phase 2 I-SPY2 trial, and also serves on the Novel Agents Committee. Dr. Rugo is the co-chair of the Triple Negative Working Group and an active member of the Translational Breast Cancer Research Consortium (TBCRC), and is the principal investigator of several TBCRC trials including a multicenter immunotherapy trial funded by the Breast Cancer Research Foundation (BCRF). She is an active member of the Alliance (formerly CALGB) Breast Committee, as well as ASCO, where she serves on the Guidelines Committee and as an editor for the Education Committee.
In addition to her research, Dr. Rugo is an active clinician committed to education and regularly lecturing locally, nationally, and internationally on subjects relating to the treatment of and supportive care for breast cancer. At UCSF, Dr. Rugo runs the Breast Forum, an open bimonthly evening educational session for breast cancer patients, families, and friends from throughout the bay area.
Dr. Rugo graduated from the University of Pennsylvania School of Medicine in 1983. She completed a residency in internal medicine and primary care followed by a fellowship in hematology and oncology at the University of California San Francisco. She was a post-doctoral fellow in immunology participating in laboratory research at Stanford University from 1988-1990. In 1990, Dr. Rugo joined the faculty at UCSF in the Division of Hematology and Oncology. Dr. Rugo has been recognized for her excellence in both patient care and in teaching of both medical students and training physicians. She has received several awards including the Bank of America Giannini Foundation Award and a UCSF Clinical Cancer Center Investigator Research Program intramural award. In 2006, she was honored for her work in Breast Cancer Research by the Friends of the Breast Care Center.
Edgardo S. Santos Castillero, MD, FACP
Founding Partner, Florida Precision Oncology R&C
Florida Precision Oncology, a division of Genesis Care
Medical Director of Research Services
Thoracic and Head/Neck Cancer Programs
Clinical Affiliate Associate Professor
Charles E. Schmidt College of Medicine
Florida Atlantic University
Secretary, Florida Society of Clinical Oncology (FLASCO)
Edgardo S. Santos Castillero, MD, FACP practices at Florida Precision Oncology (FPO), a division of Genesis Care and is a Clinical Affiliate Associate Professor at Charles E. Schmidt College of Medicine/Florida Atlantic University. Dr. Santos is a Founding Partner of FPO, Secretary of Florida American Society of Clinical Oncology (FLASCO), member of the FLASCO Foundation, member of the International Association for the Study of Lung Cancer (IASLC) membership committee, and editorial group member of IASLC Lung Cancer News. He earned his MD in 1994 at the University of Panama, School of Medicine, Republic of Panama. Dr. Santos completed his internship and residency training in internal medicine at Jackson Memorial Medical Center, University of Miami School of Medicine, Miami, Florida. He went on to complete his fellowship in hematology/oncology at the Sylvester Comprehensive Cancer Center, Miami, Florida. Dr. Santos has authored or co-authored several manuscripts in peer-reviewed journals and also serves as reviewer for several scientific publications. Dr. Santos is a member of the Editorial Board of the Expert Review series, Recent Patents on Biomarkers, and Clinical Practice. He has lectured mostly on topics related to lung cancer.
Dr. Santos is a former faculty member of University of Miami Miller School of Medicine, Miami, Florida where he held an academic rank as an Associate Professor of Medicine (2008-2012) and Tulane University Health Sciences Center, New Orleans, Louisiana (2004-2008). Dr. Santos has occupied several administrative, educational, and research leadership positions including Tulane University Principal Investigator at Southwest Oncology Group, Associate Scientific Director of Tulane Cancer Center’s Office of Clinical Research, Associate Director of the Fellowship Programs (Tulane University and University of Miami), Chief of the Hematology/Oncology Section at the Southeast Louisiana Veterans Healthcare System, Chair of the Committee Research Advisory Board, Co-Leader of Clinical Research for the Louisiana Cancer Research Consortium, Co-Leader of the Head and Neck Cancer Program at Sylvester Cancer Center, Medical Director of Cancer Research at Lynn Cancer Institute/Boca Raton Regional Hospital, and many others. He is an active member of IASLC, AACR, ASCO, ASH, ESMO, and ACP.
Amy Schippers, PA-C
Cancer Expert Now
Amy Schippers, PA is a physician assistant at St. Luke's University Health Network in Bethlehem, Pennsylvania. She completed her undergraduate degree in the fast track physician assistant program at DeSales University and then completed her master's degree at DeSales University in 2010. Since graduating as a PA she has been working in the hematology/oncology field and currently specializes in melanoma and squamous cell head/neck malignancies.
Rachna T. Shroff, MD, MS
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
Medical Director, Arizona Clinical Trials Network
Vice Chair for Clinical Research, Department of Medicine
Associate Professor of Medicine
Division of Hematology/Oncology
University of Arizona Cancer Center (UACC)
Rachna T. Shroff, MD, MS is Associate Professor of Medicine and Chief of GI Medical Oncology as well as Leader of the Gastrointestinal Clinical Research Team at the University of Arizona Cancer Center (UACC). She is the Director of UACC’s Clinical Trials Office and the Arizona Clinical Trials Network (ACTN), as well as Vice Chair of Clinical Research for the Department of Medicine. She came to UACC from MD Anderson Cancer Center in Houston, TX where she served as faculty from 2010-2018 after completing her medical oncology fellowship there.
Dr. Shroff is a clinical and translational investigator focused on developing novel therapies for pancreatic and biliary cancers. She holds multiple positions nationally due to her expertise in these areas, including serving as the Hepatobiliary Subcommittee Co-Chair for the Southwest Oncology Group (SWOG) and as a program committee member for GI ASCO. She also is a member of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. Dr. Shroff has led numerous clinical trials focusing on pancreaticobiliary tumors and is the National Principal Investigator for SWOG 1815 which is investigating a triplet chemotherapy regimen as a potential new standard of care for biliary cancers. This is based on a phase 2 study she led that is now published in JAMA Oncology. Dr. Shroff has been invited to speak at national and international meetings on topics related to targeted therapies for pancreatic and biliary cancers and has numerous peer-reviewed publications in this area.
Sara Tolaney, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Associate Director of the Susan F. Smith Center for Women’s Cancers
Dana-Farber Cancer Institute
Sara Tolaney, MD, MPH is the Associate Director for the Susan F. Smith Center for Women’s Cancers, the Director of Clinical Trials in the Breast Oncology Center, Director of Breast Immunotherapy Clinical Research, Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. Her research focuses on the development of novel therapies in the treatment of breast cancer.
Dr. Tolaney received her undergraduate degree from Princeton University and her medical degree from UC San Francisco. She subsequently completed her residency in internal medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained her Master’s in Public Health from Harvard School of Public Health. She is the recipient of the Lee M. Nadler “Extra Mile” Award, and the Innovation Award for Clinical Faculty at Dana-Farber Cancer Institute.
Dr. Tolaney has earned both a strong national and international reputation as a talented clinical investigator. She has done extensive work on de-escalating therapy for patients with stage I HER2+ breast cancer, having run both the APT and ATEMPT trials. She has been involved in development of cdk 4/6 inhibitors and led the first randomized trial of CDK 4/6 inhibition in HER2+ disease. She is also leading a series of important clinical trials investigating the use of immunotherapy in breast cancer, and had designed and conducted the first randomized trial of chemotherapy with or without checkpoint inhibition in metastatic hormone-receptor positive breast cancer. She has over 100 peer-reviewed publications and has been published in journals such as the New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology, JAMA Oncology, and PNAS.
Donald L. Trump, MD, FACP, FASCO
Founding CEO, Inova Schar Cancer Institute
Inova Health System
Professor of Medicine
University of Virginia Cancer Center
Donald L. Trump, MD, FACP, FASCO has been a leader of comprehensive cancer center science, clinical, and education programs for more than 2 decades. He has served as director of experimental therapeutics at Duke Comprehensive Cancer Center, deputy director for clinical investigations at the University of Pittsburgh Cancer Institute, and he was the president and CEO of Roswell Park Cancer Institute (RPCI) from 2007 to 2014, in which he led the successful competitive renewal of the RPCI National Cancer Institute Comprehensive Cancer Center Support Grant (CCSG) twice. From 2002 to 2007, he was co-principal investigator of the Roswell Park CCSG, associate institute director, and senior vice president for clinical investigation. He has been co-principal investigator or principal investigator on numerous peer-reviewed National Institutes of Health, Department of Defense, and American Cancer Society grants.
In 2015, Dr. Trump moved to northern Virginia to take leadership of the newly established Inova Schar Cancer Institute (ISCI), a part of the Inova Health System, and was appointed professor of medicine at the University of Virginia. In early 2019, Dr. Trump retired from his ISCI leadership position. Since retirement from active practice, Dr. Trump continues to act as a senior advisor to several cancer centers and drug development companies. He and his colleague Eric Rosenthal are writing a book recounting the history of cancer centers in the US after the National Cancer Act of 1971 and influences of these centers on the remarkable progress that has occurred in cancer research and cancer care in the past half century, to be published by Rowan and Littlefield in 2021.
Dr. Trump’s clinical and research program has focused on developing new approaches in genitourinary (GU) cancer treatment, especially in prostate cancer, with a particular emphasis on the evaluation of the biological and clinical roles of vitamin D and vitamin D analogues in GU cancer etiology and therapeutics. He has led institutional and cooperative group trials in new treatment approaches to GU malignancies, and has developed several vitamin D–based clinical studies. He has carried out detailed pharmacokinetic/pharmacodynamic assessments of calcitriol (the most active vitamin D compound) given by several schedules and routes of administration, and collaborated in preclinical assessments of vitamin D–based therapeutics and translational studies emanating from these clinical trials.
Adrienne M. Vazquez Guerra, MSN, ACNP-BC, AOCNP
Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine
Mrs. Adrienne Vazquez Guerra is a board-certified acute care nurse practitioner. Mrs. Vazquez Guerra has worked in various roles within oncology which include inpatient oncology/hematology, outpatient medical thoracic oncology, outpatient infusion center, thoracic oncology clinical trials, precision medicine, survivorship and management of several clinical programs. Mrs. Vazquez Guerra is an Advanced Oncology Certified Nurse Practitioner® (AOCNP) and is the outgoing ONCC national chair for the item writing and test development national committees for the AOCNP board exam. She is a past president of the Miami-Dade chapter of the Oncology Nursing Society.
Her current role at Sylvester Comprehensive Cancer Center is nurse practitioner within the Cancer Survivorship program.
Julie M. Vose, MD, MBA
Neumann M. and Mildred E. Harris Professor
University of Nebraska Medical Center
Julie M. Vose, MD, MBA is the Neumann M. and Mildred E. Harris Professor and Chief of the Division of Oncology/Hematology at the University of Nebraska Medical Center in Omaha, Nebraska. In addition, she is a past president of the American Society of Clinical Oncology.
Dr. Vose received her medical degree, completed her residency in internal medicine as chief resident, and completed a fellowship in hematology and oncology at the University of Nebraska Medical Center. In addition, she completed a sabbatical at Stanford University, and continued her education by obtaining an MBA in Health Administration from the University of Colorado Business School.
Dr. Vose has focused her career on translational research improving the therapy of non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma by developing a focused translational research program evaluating novel therapies, such as radiolabeled monoclonal antibodies, idiotype vaccine therapies, pathway-directed agents, stem cell transplantation, and CAR T-cell therapy. Further, her funding record and publications in NHL therapy and transplantation research have substantially added to the research and knowledge base for lymphoma therapy. As a result of her NHL research, Dr. Vose has been recognized nationally and internationally through worldwide research awards and invited lectureships.
H. Jack West, MD
Associate Clinical Professor, Medical Oncology
Clinical Executive Director, AccessHope
City of Hope Comprehensive Cancer Center
Dr. West is a thoracic oncology specialist and an Associate Clinical Professor in Medical Oncology at City of Hope Comprehensive Cancer Center. He also serves as Clinical Executive Director of AccessHope, which is a program of remote cancer consult services.
Dr. West received an MPhil in experimental biology from Cambridge University on a Fulbright Scholarship and a medical degree (magna cum laude) from Harvard Medical School, where he also conducted research as a Howard Hughes Medical Student Fellow. His postdoctoral training included an internship and residency in internal medicine at the Harvard-affiliated Brigham and Women’s Hospital, Boston, MA, followed by a fellowship in medical oncology at the Fred Hutchinson Cancer Research Center/University of Washington in Seattle, WA.
In late 2002, he moved to Swedish Cancer Institute in Seattle, where he served for over 16 years as Medical Director of the Thoracic Oncology Program, overseeing a broad array of clinical care and research responsibilities. In March 2019, he moved to the City of Hope to dedicate his focus on innovative approaches to delivering sub-specialist expertise across a broader geography, using tools such as remote case reviews and telemedicine consultations.
He has authored dozens of papers and chairs several CME programs and symposia internationally on thoracic oncology, novel educational approaches, and social media in cancer care.
In addition to these activities, he is the Founder and President of Global Resource for Advancing Cancer Education (GRACE); web editor for JAMA Oncology; regular correspondent for Medscape; and contributing author and section editor in lung cancer for UpToDate.